Sagimet Biosciences (SGMT) Cash from Operations: 2022-2024
Historic Cash from Operations for Sagimet Biosciences (SGMT) over the last 3 years, with Dec 2024 value amounting to -$42.4 million.
- Sagimet Biosciences' Cash from Operations fell 404.49% to -$19.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$38.5 million, marking a year-over-year change of. This contributed to the annual value of -$42.4 million for FY2024, which is 78.55% down from last year.
- Per Sagimet Biosciences' latest filing, its Cash from Operations stood at -$42.4 million for FY2024, which was down 78.55% from -$23.8 million recorded in FY2023.
- Sagimet Biosciences' Cash from Operations' 5-year high stood at -$23.8 million during FY2023, with a 5-year trough of -$42.4 million in FY2024.
- Its 3-year average for Cash from Operations is -$30.2 million, with a median of -$24.5 million in 2022.
- In the last 5 years, Sagimet Biosciences' Cash from Operations grew by 2.96% in 2023 and then tumbled by 78.55% in 2024.
- Over the past 3 years, Sagimet Biosciences' Cash from Operations (Yearly) stood at -$24.5 million in 2022, then increased by 2.96% to -$23.8 million in 2023, then slumped by 78.55% to -$42.4 million in 2024.